

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: AION THERAPEUTIC INC. (formerly, Osoyoos Cannabis Inc.)  
(the "Issuer")

Trading Symbol: AION

Number of Outstanding Listed Securities: 124,804,794

Date: April 30, 2021

#### Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer is focused on utilizing science, research, treatment, data mining and artificial intelligence to develop combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals using compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi, and other psychedelic formulations and their related medicinal global intellectual property protection.

On April 12, 2021, the Issuer announced that it had retained KCSA Strategic Communications ("**KCSA**"), a leading New York City-based communications firm. KCSA will work with management to create a comprehensive, strategic communications program to lead the Issuer's public and investor relations programs. Since KCSA's inception, nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies with an expertise in several verticals including the psychedelics and cannabis industries. The engagement is designed to increase the awareness and help enhance the profile of the Issuer in the marketplace. For its services supporting the Issuer's public relations and investor relations efforts, KCSA will receive Usd. \$15,000 per month. The term of the engagement will be initially six months and then ongoing on a month-to-month basis. The Issuer has the right to terminate the relationship with KCSA on 90 days' notice.

On April 21, 2021, the Issuer announced its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "**Aion Mushroom Preparations**" or "**Preparations**") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

As shown in recently completed third-party independent and carefully controlled 3D-spheroid cell culture studies performed at BIOENSIS laboratories, these cytotoxicity studies demonstrated direct killing of the breast cancer cells by the Aion Mushroom Preparations, which suggests such preparations may be effective in treating HER2+ breast cancer, ER+/PR+ breast cancer, and the very difficult to treat triple-negative breast cancer, with each of these types of breast cancers tested independently.

In separate independent studies at BIOENSIS laboratories using the Antibody-Dependent Cellular Cytotoxicity (ADCC) assay and the Antibody-Dependent Cellular Phagocytosis (ADCP) assay, the Aion Mushroom Preparations also demonstrated enhanced cell killing of HER2+ breast cancer cells via stimulation of the immune system. The Preparations showed similar effectiveness as trastuzumab, a monoclonal antibody treatment sold under the brand name Herceptin, manufactured by Roche and is a US FDA approved medication useful for treating HER2+ breast cancer that is either early-stage or advanced-stage/metastatic. Herceptin (trastuzumab) is the leading breast cancer drug. Other FDA approved biosimilar trastuzumab products include: Trazimera (Pfizer), Kanjinti (Amgen), Ontruzant (Merck), Herzuma (Teva), and Ogivri (Mylan). When Aion Mushroom Preparations were combined with Trastuzumab, there was a greater than 60% increase in the killing of HER2+ breast cancer cells when compared to Trastuzumab used alone.

Based on these results, Dr. Herbert A. Fritsche, Chief Science Officer of Aion Therapeutic and former Professor and Director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center, stated, "The extremely exciting results obtained from these independent 3D cell culture studies suggests that when appropriate Aion Mushroom Preparations are used together, they may offer a dual approach to the killing of HER2+ breast cancer cells through two separate and distinct pathways (direct cytotoxicity and antibody dependent cytotoxicity). The significant improvement in cancer cell cytotoxicity that was observed when the Preparations were combined with Trastuzumab warrants immediate further investigation in breast cancer patients." Dr. Fritsche continued, "We look forward to the next step of initiating clinical trials of the Aion Mushroom Preparations with and without Herceptin (and other trastuzumab biosimilars) for the treatment of HER2+ breast cancer patients as well as the Aion Mushroom Preparations alone in ER+/PR+ breast cancer and triple-negative breast cancer patients."

## **2. Provide a general overview and discussion of the activities of management.**

During the month of April 2021, management has been focused on furthering its development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals using compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi, and other psychedelic formulations and their related medicinal global intellectual property protection.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

8. **Describe the acquisition of new customers or loss of customers.**

None.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**  
None.
10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**  
None.
11. **Report on any labour disputes and resolutions of those disputes if applicable.**  
None.
12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**  
None.
13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**  
None.
14. **Provide details of any securities issued and options or warrants granted.**  
None.
15. **Provide details of any loans to or by Related Persons.**  
None.
16. **Provide details of any changes in directors, officers or committee members.**  
None.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

In March 2020, the World Health Organization declared a global pandemic related to the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19". This has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures which include the implementation of travel bans, self-imposed quarantine periods and social distancing have caused material disruption to businesses resulting in a global economic disruption. Global equity markets have experienced historic volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize domestic economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions.

The Issuer had operated primarily on a virtual basis prior to the COVID-19 pandemic. Therefore, the implementation of travel bans, self-imposed quarantine periods, social distancing and general closure of non-essential businesses in response to COVID-19 has not materially impacted the Issuer with its day-to-day operations. Furthermore, the Issuer does not expect the COVID-19 pandemic to have a material adverse effect on the Issuer's results of operations.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 4, 2021.

Graham Simmonds  
Name of Director or Senior  
Officer

"Graham Simmonds" (signed)  
Signature

Chief Executive Officer  
Official Capacity

<b>Issuer Details</b> Name of Issuer  AION THERAPEUTIC INC.	For Month End  March 2021	Date of Report YY/MM/DD  21/05/04
Issuer Address 45 Sheppard Avenue East, Suite 703		
City/Province/Postal Code Toronto, Ontario, M2N 5W9	Issuer Fax No. N/A	Issuer Telephone No. (416) 843-2881
Contact Name  Graham Simmonds	Contact Position CEO	Contact Telephone No.  (416) 843-2881
Contact Email Address <a href="mailto:graham.simmonds@aiontherapeutic.com">graham.simmonds@aiontherapeutic.com</a>	Web Site Address <a href="http://www.aiontherapeutic.com">www.aiontherapeutic.com</a>	